Tocagen

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, May 28, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state...

Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders

Tocagen Inc. (TOCA) Tocagen and Forte Biosciences Announce Merger (Transcript)

Tocagen Inc (NASDAQ: TOCA) shares were tumbling to an all-time low Thursday following an adverse clinical trial readout.

Tocagen Shares Plummet On Failed Late-Stage Brain Cancer Study

Shares of Tocagen Inc. TOCA, +11.47% plummeted 82% on heavy volume toward a record low, enough to pace all premarket decliners Thursday, after the gene company said a late-stage trial of its brain cancer treatment failed to meet its primary endpoint of survival compared with standard of care treatment.

Tocagen's stock plunges toward record low after late-stage trial of cancer treatment misses primary endpoint

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

Implied Volatility Surging for Tocagen (TOCA) Stock Options

TOCAGEN INC (TOCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TOCAGEN INC (TOCA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

The final data read-out of Toca 5 Pivotal phase III trial in patient with Recurrent Brain Cancer anticipated in Q4 2019.

Tocagen: Free Ticket For Run-Up Ride

Investors overreacted to Tocagen’s recent announcement that an Independent Data Monitoring Committee (IDMC) gave its brain cancer drug clinical trials the go-ahead to continue.

Tocagen: An Undeserved Selloff

Do Options Traders Know Something About Tocagen (TOCA) Stock We Don't?

An interim look at the company's experimental brain cancer treatment didn't reveal the result investors wanted.

Here's Why Tocagen's Having a Rough Day

Are Options Traders Betting on a Big Move in Tocagen (TOCA) Stock?

Today, we take a "deep-dive" on an interesting developmental name in oncology named Tocagen based in sunny San Diego.

Taking A Look At Tocagen

News for Tocagen Stock (TOCA)